Literature DB >> 24749693

Risk factors for facial melasma in women: a case-control study.

A C Handel1, P B Lima, V M Tonolli, L D B Miot, H A Miot.   

Abstract

BACKGROUND: Melasma is a localized chronic acquired hypermelanosis, common in adult women and which has an important impact on their life quality. Its pathology is unknown, despite some recognized triggering factors.
OBJECTIVE: To evaluate risk factors for developing facial melasma in women.
METHODS: This was a case-control study involving adult women with or without facial melasma, paired by age. Variables were grouped into hierarchical levels: personal characteristic data, exposure variables, links to hormonal stimuli and the State-Trait Anxiety Inventory questionnaire, Brazilian version. The data were analysed using conditional multiple logistic regression.
RESULTS: We evaluated 207 patients and 207 controls. The mean age was 38 years. Cases differed from controls for phototype, Amerindian ancestry [odds ratio (OR) 2·59], years of beach or rural residence (OR 1·06), time exposed to sun at work (OR 1·65), time exposed to sun in leisure activities (OR 1·04), antidepressant/anxiolytic use (OR 4·96), menstrual irregularity (OR 3·83), pregnancy history (OR 3·59), years of oral contraceptive use (OR 1·23) and anxiety scores (OR 1·08). A family history of melasma was reported in 61% of cases and 13% of controls (OR 10·40).
CONCLUSIONS: Facial melasma is independently associated with elements linked to pigmentation capacity, family ancestry, chronic sun exposure, sexual hormone stimuli, psychotropics and anxiety traits.
© 2014 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24749693     DOI: 10.1111/bjd.13059

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  17 in total

Review 1.  [Melasma : An update on the clinical picture, treatment, and prevention].

Authors:  S Becker; C Schiekofer; T Vogt; J Reichrath
Journal:  Hautarzt       Date:  2017-02       Impact factor: 0.751

2.  Sebocytes contribute to melasma onset.

Authors:  Enrica Flori; Arianna Mastrofrancesco; Sarah Mosca; Monica Ottaviani; Stefania Briganti; Giorgia Cardinali; Angela Filoni; Norma Cameli; Marco Zaccarini; Christos C Zouboulis; Mauro Picardo
Journal:  iScience       Date:  2022-02-04

Review 3.  Dermatology: how to manage facial hyperpigmentation in skin of colour.

Authors:  Siddiq Moolla; Yvette Miller-Monthrope
Journal:  Drugs Context       Date:  2022-05-31

4.  Low-power Fractional Carbon Dioxide Laser Followed by Jessner's Peel versus Jessner's Peel Alone for the Treatment of Melasma.

Authors:  Eman Elmorsy; Nouran Aboukhadr; Maha Tayyeb; Alsayeda A A Taha
Journal:  J Clin Aesthet Dermatol       Date:  2021-02-01

Review 5.  Melasma: A Condition of Asian Skin.

Authors:  Michelle X Wu; Ruth Antony; Harvey N Mayrovitz
Journal:  Cureus       Date:  2021-04-10

6.  Etiopathogenetic factors, thyroid functions and thyroid autoimmunity in melasma patients.

Authors:  Seray Külcü Çakmak; Nimet Özcan; Arzu Kılıç; Suha Koparal; Ferda Artüz; Atıl Çakmak; Kenan Köse
Journal:  Postepy Dermatol Alergol       Date:  2015-10-29       Impact factor: 1.837

Review 7.  The Development of Sugar-Based Anti-Melanogenic Agents.

Authors:  Bum-Ho Bin; Sung Tae Kim; Jinhyuk Bhin; Tae Ryong Lee; Eun-Gyung Cho
Journal:  Int J Mol Sci       Date:  2016-04-16       Impact factor: 5.923

8.  Psychometrican analysis and dimensional structure of the Brazilian version of melasma quality of life scale (MELASQoL-BP).

Authors:  Camila Fernandes Pollo Maranzatto; Hélio Amante Miot; Luciane Donida Bartoli Miot; Silmara Meneguin
Journal:  An Bras Dermatol       Date:  2016 Jul-Aug       Impact factor: 1.896

9.  Clinico-epidemiological Study and Quality of Life Assessment in Melasma.

Authors:  Ravali Yalamanchili; Veeranna Shastry; Jayadev Betkerur
Journal:  Indian J Dermatol       Date:  2015 Sep-Oct       Impact factor: 1.494

Review 10.  Melasma: an Up-to-Date Comprehensive Review.

Authors:  Oluwatobi A Ogbechie-Godec; Nada Elbuluk
Journal:  Dermatol Ther (Heidelb)       Date:  2017-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.